ICD-10-PCS Billable Code

DB15B6Z

Brachytherapy Pleura to None with Cesium 131 (Cs-131), Low Dose Rate (LDR) Approach

Procedural Specifications

Clinical Axis Detail Definition
SectionD Radiation Therapy
Body SystemB Respiratory System
Operation1 Brachytherapy
Body Part5 Pleura
ApproachB Low Dose Rate (LDR)
Device6 Cesium 131 (Cs-131)
QualifierZ None

Procedure Overview

Brachytherapy of the respiratory system places a radioactive source directly inside or immediately next to lung or airway tissue, most often through a bronchoscope that guides a catheter to the tumor site. This lets clinicians deliver a concentrated dose to a small area, such as a tumor growing into the bronchus and narrowing the airway, while sparing surrounding lung tissue that an external beam would have to pass through.

It is frequently used to relieve breathing difficulty caused by an obstructing endobronchial tumor, and it can also serve as a targeted boost after a course of external beam treatment. The radioactive source may be left in place temporarily during a single procedure or, less commonly, implanted for a longer period.

Anatomy & Axis Detail

Pleura

Brachytherapy of the pleura involves placing radioactive sources against or within the pleural space, most often intraoperatively after surgical resection or debulking of malignant pleural mesothelioma, to deliver concentrated dose to residual disease along the chest wall lining. Because the pleura forms a large, curved surface area following the contours of the lung and rib cage, source placement must be planned to achieve even coverage across an irregular geometry while protecting the lung, heart, and diaphragm from excessive dose. This approach is typically used as an adjunct to surgery rather than as a standalone treatment. Coders should confirm that sources are placed against the pleural surface itself, distinguishing this from beam radiation directed at the same region from outside the body.

Modality Qualifier: Low Dose Rate (LDR)

Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.

Isotope: Cesium 131 (Cs-131)

Cesium-131 is a permanent-seed brachytherapy isotope, similar in application to I-125 and Pd-103, implanted for prostate and other solid tumors, but distinguished by its notably shorter half-life of roughly 9.7 days. This compresses dose delivery into a shorter window than either I-125 or Pd-103, which can be clinically relevant for tumor kinetics and post-implant management.

Coding & Documentation

Coding this family depends on documentation confirming that a radioactive source was placed within or adjacent to respiratory tissue, including the specific structure treated, the isotope or source type, and whether the implant was temporary or intended to remain in place. The procedure note from the bronchoscopy or interventional session is the key source document. A common mistake is coding the catheter or applicator placement itself as a separate Medical and Surgical procedure when it was performed solely to deliver the radiation, rather than recognizing it as part of the brachytherapy episode. Coders also sometimes miss the qualifier distinguishing a temporary source from a permanent one.

Commonly Confused With

The main point of confusion is with beam radiation, since both treat similar tumors - the distinction is strictly whether the radiation source is inserted into the body or delivered from an external device. It can also be confused with a diagnostic or therapeutic bronchoscopy performed for other reasons; if the bronchoscope is used purely as the delivery route for a radioactive source, the encounter is coded as brachytherapy rather than as a separate endoscopic procedure.